FindTrial
Sign In

Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients

Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04389645
Enrollment
52
Registered
2020-05-15
Start date
2020-04-07
Completion date
2020-05-12
Last updated
2020-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

The proposed project will pilot incorporation of rapid serial measurements of IP-10 into a CDS tool for moderate and severe COVID-19 patients. The tool was applied to all comers with confirmed COVID-19 diagnosis at a secondary medical center in Israel.

Interventions

DIAGNOSTIC_TESTIP-10 in CDS protocol

Dynamic IP-10 measurements in hospitalized COVID-19 positive patients

Sponsors

MeMed Diagnostics Ltd.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* PCR- positive for COVID-19

Exclusion criteria

* \<18 years of age

Design outcomes

Primary

MeasureTime frame
IP-10 levelsup to 24 months

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026